WALTHAM, Mass. (Oct. 27, 2008) — IntrinsiQ, the expert source of oncology insight, today launches IntelliDose 3.8, creating an intuitive new user experience to manage and track increasingly complex chemotherapy regimens.
IntelliDose 3.8 tackles the biggest challenges in automating chemotherapy: How to encourage every member of the practice to “buy in” – the oncologist, the pharmacist, the nurses and the practice managers – and provide the functionality and flexibility required to manage the wide range of therapies and procedures in an oncology setting.
“We’re realizing IntelliDose’s full promise with version 3.8: standardized treatment decisions, safeguards against human error, and streamlined efficiency across our fast-paced practice,” said Genean Page, oncology nurse and clinical research coordinator of Washington-based Olympic Hematology & Oncology Associates, PLLC.
New features in IntrinsiQ’s flagship clinical oncology software suite include enhancements to two core modules:
Created by an oncologist and incorporating a decade’s worth of field-tested user input, IntelliDose gives all cancer care stakeholders accuracy and insight into patients’ complex courses of treatment. Today, more than 500 oncologists nationwide use it to treat nearly 20,000 patients every month.
“In just the past five years, cancer caregivers have had to keep up with a relentless pace of pharmaceutical innovations – introducing thousands more options and combinations for therapy,” said Ted Owens, division general manager of IntrinsiQ’s IntelliDose software division. “The new complexity that makes chemotherapy almost impossible to manage with paper and pen also makes it incredibly important to choose a clinical software suite that was designed for the oncology specialty.”
The Paperless Practice: Start with a CPOE
As a computerized physician order entry (CPOE) software solution, IntelliDose is an easy first step toward achieving a paperless practice. Practice managers simply start every new patient regimen in the software, without months – or even years – of data migration from paper charts into electronic medical records (EMRs).
IntelliDose allows practices to quickly automate its core function of chemotherapy administration. It also seamlessly integrates with all of the leading practice-management and hospital-wide EMR suites, for long-term investment protection.
IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.
Ted Owens
(781) 434-3331
ted.owens@intrinsiq.com
Lesley Cannata
(617) 969-9192
lcannata@corporateink.com